Soligenix IncNASDAQ:SNGXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8800/ 1
- Ask / Lots0.9100/ 133
- Open / Previous Close0.0000 / 0.8700
- Day Range---
- 52 Week Range
- Volume587
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNGX |
|---|---|---|
| 09:32 ET | 1310 | 0.8598 |
| 09:41 ET | 2000 | 0.86 |
| 09:48 ET | 184 | 0.841 |
| 09:54 ET | 100 | 0.85 |
| 09:56 ET | 355 | 0.85 |
| 10:08 ET | 1510 | 0.8598 |
| 10:26 ET | 10000 | 0.8416 |
| 10:30 ET | 300 | 0.841601 |
| 10:33 ET | 1400 | 0.8598 |
| 10:35 ET | 117 | 0.859699 |
| 10:39 ET | 100 | 0.8598 |
| 10:44 ET | 100 | 0.8549 |
| 10:48 ET | 100 | 0.8501 |
| 11:04 ET | 3500 | 0.8584 |
| 11:08 ET | 4998 | 0.86 |
| 11:13 ET | 600 | 0.86 |
| 11:24 ET | 803 | 0.8565 |
| 11:26 ET | 7700 | 0.8555 |
| 11:29 ET | 19400 | 0.8573 |
| 11:31 ET | 100 | 0.8549 |
| 11:40 ET | 300 | 0.8549 |
| 11:42 ET | 4029 | 0.85 |
| 11:44 ET | 100 | 0.8501 |
| 11:45 ET | 500 | 0.8501 |
| 11:47 ET | 1100 | 0.8501 |
| 11:49 ET | 270 | 0.85 |
| 11:51 ET | 2340 | 0.85 |
| 11:54 ET | 100 | 0.8501 |
| 12:07 ET | 100 | 0.855001 |
| 12:20 ET | 1750 | 0.855051 |
| 12:27 ET | 100 | 0.86 |
| 12:54 ET | 1000 | 0.855051 |
| 01:17 ET | 125 | 0.8599 |
| 01:19 ET | 500 | 0.859899 |
| 01:32 ET | 600 | 0.8502 |
| 01:33 ET | 100 | 0.86 |
| 01:50 ET | 933 | 0.8506 |
| 02:11 ET | 500 | 0.8504 |
| 02:13 ET | 100 | 0.8504 |
| 02:22 ET | 4522 | 0.8853 |
| 02:27 ET | 100 | 0.8505 |
| 02:31 ET | 1000 | 0.8599 |
| 02:54 ET | 145 | 0.8506 |
| 02:56 ET | 300 | 0.8506 |
| 03:07 ET | 456 | 0.8506 |
| 03:16 ET | 100 | 0.86 |
| 03:21 ET | 553 | 0.8554 |
| 03:34 ET | 2052 | 0.8554 |
| 03:39 ET | 4800 | 0.8599 |
| 03:41 ET | 2652 | 0.8703 |
| 03:43 ET | 100 | 0.87 |
| 03:45 ET | 550 | 0.8502 |
| 03:54 ET | 100 | 0.8704 |
| 03:59 ET | 1500 | 0.87 |
Today
BRIEF-Soligenix Inc - Revenues For Quarter Ended June 30 Were $0.4 Mln As Compared To $0.2 Mlm, A Year Earlier, from 55 minutes ago by Thomson Reuters
55 minutes ago by Thomson ReutersSoligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results, from 1 hour ago by PR Newswire
1 hour ago by PR Newswire
Jul 27, 2022
Soligenix Secures Agreement With FDA for HyBryte's Initial Pediatric Study Plan; Shares Climb, from 10:21AM ET on Wednesday Jul 27, 2022 by MT Newswires
10:21AM ET on Wednesday Jul 27, 2022 by MT NewswiresBRIEF-Soligenix Receives Agreement From FDA On Initial Pediatric Study Plan For Hybryte For Treatment Of Cutaneous T-Cell Lymphoma, from 8:18AM ET on Wednesday Jul 27, 2022 by Thomson Reuters
8:18AM ET on Wednesday Jul 27, 2022 by Thomson ReutersSoligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma, from 7:30AM ET on Wednesday Jul 27, 2022 by PR Newswire
7:30AM ET on Wednesday Jul 27, 2022 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Soligenix Inc | 37.0M | -2.5x | --- |
Aptinyx Inc | 46.7M | -0.5x | --- |
Ainos Inc | 31.2M | -5.2x | --- |
Trevena Inc | 39.7M | -0.7x | --- |
NanoViricides Inc | 35.6M | -3.6x | --- |
Oncotelic Therapeutics Inc | 34.1M | -2.9x | --- |
Company Information
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing products to treat rare diseases. The Company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The Company's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).
Contact Information
- Headquarters
- SUITE C-10, 29 EMMONS DRIVEPRINCETON, NJ, United States 08540
- Phone
- 609-538-8200
- Fax
- 609-452-6467
Executives
- Chairman of the Board, Chief Executive Officer and President
- Christopher Schaber
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- Jonathan Guarino
- Senior Vice President, Chief Scientific Officer
- Oreola Donini
- Senior Vice President and Chief Medical Officer
- Richard Straube
- Independent Director
- Gregg Lapointe
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.0M |
|---|---|
Revenue (TTM) | $864.7K |
Shares Outstanding | 43.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-0.35 |
Book Value | $0.25 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | 42.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,698.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
